While these B8-IgA antibodies maintained neutralizing activities against SARS-CoV-2 like B8-IgG1, they displayed distinct in vivo effects, with clear differences in their capacity to modulate viral infection in the NT. The gene discussed is CD79A; the disease is viral infectious disease.